Number of patients with myositis with myositis-specific or associated autoantibodies
| Antibody | Adult-onset IIM | Juvenile-onset IIM | Total number positive (Adult+juvenile-onset) | |||
| Number tested | Number antibody positive | Number tested | Number antibody positive | |||
| Jo-1 | 1937 | 325 (16.8%) | 447 | 7 (1.6%) | 332 | |
| TIF1 | 1697 | 91 (5.4%) | 356 | 106 (29.8%) | 197 | |
| PM/Scl | 1883 | 120 (6.4%) | 457 | 16 (3.5%) | 136 | |
| Mi-2 | 1884 | 87 (4.6%) | 456 | 17 (3.7%) | 104 | |
| NXP2 | 1502 | 28 (1.9%) | 360 | 65 (18.1%) | 93 | |
| cN1A | 232 | 46 (19.8%) | 81 | 18 (22.2%) | 64 | |
| SRP | 1822 | 45 (2.5%) | 457 | 0 | 45 | |
| HMGCR | 1264 | 51 (4.0%) | 130 | 1 (0.8%) | 52 | |
| MDA5 | 1674 | 18 (1.1%) | 402 | 17 (4.2%) | 35 | |
| SAE | 1518 | 31 (2.0%) | 397 | 0 | 31 | |
| PL7 | 1927 | 23 (1.2%) | 457 | 0 | 23 | |
| PL12 | 1927 | 11 (0.6%) | 457 | 0 | 11 | |
Myositis-specific/associated autoantibodies n>10 in cohort, stratified by adult-onset and juvenile-onset disease. Frequency is of those patients tested for each autoantibody within the cohort, where testing was not necessarily random.
IIM, idiopathic inflammatory myopathies.